Skip to content

Press Releases

View:
 
Press Releases
All Releases
Nov 5, 2013
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announc...
Oct 30, 2013
Represents Company's First Clinical Study in Robust Phase 2b Program PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (L...
Sep 24, 2013
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announc...
Sep 10, 2013
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announc...
Sep 3, 2013
Conference Call Today at 8:30 a.m. ET PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with ...
Aug 30, 2013
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announce...
Aug 12, 2013
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provide...
Jul 16, 2013
What: Esperion Therapeutics, Inc. [ESPR], a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, will visit the NASDAQ MarketSite in Times Square in celebration of its recent ...
Jul 11, 2013
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announc...
Jun 26, 2013
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the pricing of its ...
Jun 9, 2013
Plymouth, Mich., June 7, 2013 -- Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced positive top-line results from a Phase 2a clinical study...
May 2, 2013
LAKE BUENA VISTA, Fla., [May 2, 2013] -- Esperion Therapeutics, Inc., a privately-held clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic disorders, today announce...
Apr 26, 2013
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic disorders, today announced that it has comple...
Jan 7, 2013
Plymouth, MI [Jan 7, 2013] - Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo. ETC-1002 therapy w...
Jan 4, 2013
PLYMOUTH, MI [Jan 4, 2013] - Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced that Tim Mayleben has been named president and CEO of the company.  Roger Newton, Ph.D., FAHA, who is the founder of Esperion and has been serving as its president and CEO, wil...
= add release to Briefcase